RHY 0.00% 4.7¢ rhythm biosciences limited

Ann: Proposed issue of securities - RHY, page-17

  1. 23 Posts.
    lightbulb Created with Sketch. 1
    "Not only would way more people happily submit to the test but the savings to the health industry of having to avoid a boatload of unnecessary colonoscopies"

    Actually, this is incorrect "unnecessary colonoscopies" is driven by the false positive rate that is a function of specificity of the assay. FIT has higher specificity than ColoSTAT (96% versus 91% hence FP rates of 4% and 9% respectively).

    In other words, for every 50K people screened (assuming a CRC prevalence of 0.49%) then FIT will produce ~1,800 FP / unnecessary colonoscopies but ColoSTAT will be ~4,500 unnecessary colonoscopies.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.